Article thumbnail

Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges

By Eung-Jun Im, Jessie P. Hong, Yaowaluck Roshorm, Anne Bridgeman, Sven Létourneau, Peter Liljeström, Mary Jane Potash, David J. Volsky, Andrew J. McMichael and Tomáš Hanke

Abstract

Immunodominance in T cell responses to complex antigens like viruses is still incompletely understood. Some data indicate that the dominant responses to viruses are not necessarily the most protective, while other data imply that dominant responses are the most important. The issue is of considerable importance to the rational design of vaccines, particularly against variable escaping viruses like human immunodeficiency virus type 1 and hepatitis C virus. Here, we showed that sequential inactivation of dominant epitopes up-ranks the remaining subdominant determinants. Importantly, we demonstrated that subdominant epitopes can induce robust responses and protect against whole viruses if they are allowed at least once in the vaccination regimen to locally or temporally dominate T cell induction. Therefore, refocusing T cell immune responses away from highly variable determinants recognized during natural virus infection towards subdominant, but conserved regions is possible and merits evaluation in humans

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3098219
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). A previously unrecognized H2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge.
  2. (2000). AIDS. Escape from the immune system.
  3. (1988). An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility moleculerestricted murine cytotoxic T lymphocytes.
  4. (2009). Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.
  5. (2004). Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
  6. (2006). CD8 T cell competition for dendritic cells in vivo is an early event in activation.
  7. (2007). Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus.
  8. (2003). Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation.
  9. (2007). Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells.
  10. (2001). Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.
  11. (2007). Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference.
  12. (2002). Competition between CTL narrows the immune response induced by primeboost vaccination protocols.
  13. (2006). Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.
  14. (2009). Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses.
  15. (2003). Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
  16. (2006). Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes.
  17. (2008). Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity.
  18. (2007). Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination.
  19. (2000). Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
  20. (2007). Design and pre-clinical evaluation of a universal HIV-1 vaccine.
  21. (2002). Design and Validation of an ELISPOT Assay for Use in Clinical Trials of Candidate HIV Vaccines.
  22. (2010). Designing CD8+ T cell vaccines: it’s not rocket science (yet).
  23. (1995). Differences in the recognition of CTL epitopes during primary and secondary responses to herpes simplex virus infection in vivo.
  24. (2002). Diversity considerations in HIV-1 vaccine selection.
  25. (1998). Enhanced immunogenicity for CD8 + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
  26. (2002). Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
  27. (2002). Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.
  28. (2004). HIV and SIV CTL escape: implications for vaccine design.
  29. (2004). HIV evolution: CTL escape mutation and reversion after transmission.
  30. (2003). HIV vaccines 1983-2003.
  31. (2007). HIV-1 group M conserved elements vaccine.
  32. (1999). Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses.
  33. (2003). Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression.
  34. (2000). In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.
  35. (2003). Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.
  36. (2010). Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
  37. (1998). McMichael A
  38. (2008). Measuring HIV-1-specific T cell immunity: how valid are current assays?
  39. (2006). Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.
  40. (2007). Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution.
  41. (2009). Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101 + patients protected mice against chimaeric EcoHIV challenge.
  42. (2010). Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.
  43. (2007). Portable flanking sequences modulate CTL epitope processing.
  44. (1997). Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.
  45. (2006). Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice.
  46. (1995). Presentation of endogenous peptide/ MHC class I complexes is profoundly influenced by specific C-terminal flanking residues.
  47. (2004). Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture.
  48. (1998). Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides.
  49. (2002). Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
  50. (2008). Relevance of studying T cell responses in SIVinfected rhesus macaques.
  51. (2004). Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination.
  52. (2003). Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.
  53. (2000). Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides.
  54. (2007). Short communication: preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice.
  55. (2001). Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.
  56. (2002). T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens.
  57. (2002). T cells down-modulate peptide-MHC complexes on APCs in vivo.
  58. (2009). The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.
  59. (2010). The immune response during acute HIV-1 infection: clues for vaccine development.
  60. (1998). The MHC class Irestricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D.
  61. (2004). The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKTmediated cytotoxicity against multiple targets in vitro and in vivo.
  62. (1994). Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus.
  63. (2005). Toll-like receptor 3 promotes cross-priming to virus-infected cells.
  64. (2001). Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities.
  65. (1997). Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice.
  66. (2007). Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
  67. (1998). Viral Immune evasion due to persistence of activated T cells without effector function.